Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Cardinal Glennon Children’s Medical Center · Angeles Clinic and Research Institute · +1 more institution
Abstract
Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity…
Citation impact
- FWCI
- 87.52
- Percentile
- 100%
- References
- 26
Authors
17- ABAndrea B. ApoloCorresponding
Cardinal Glennon Children’s Medical Center, Angeles Clinic and Research Institute, Spanish Oncology Genitourinary Group
- JRJeffrey R. Infante
Cardinal Glennon Children’s Medical Center, Angeles Clinic and Research Institute, Spanish Oncology Genitourinary Group
- ASAni Sarkis Balmanoukian
Cardinal Glennon Children’s Medical Center, Angeles Clinic and Research Institute, Spanish Oncology Genitourinary Group
- MRManish R. Patel
Cardinal Glennon Children’s Medical Center, Angeles Clinic and Research Institute, Spanish Oncology Genitourinary Group
- DWDing Wang
Cardinal Glennon Children’s Medical Center, Angeles Clinic and Research Institute, Spanish Oncology Genitourinary Group
Topics & keywords
- Medicine
- Avelumab
- Internal medicine
- Metastatic Urothelial Carcinoma
- Interquartile range
- Tolerability
- Adverse effect
- Gastroenterology
- Good health and well-being